About US
Contact us
-
US government appeals Gilead's trial win in Truvada, Descovy patent fightAs Gilead Sciences tussles with a web of HIV drug litigation, a high-stakes case tied to patents for prevention medicinesis coming back to test the drugmaker. On Friday, the U.S. Department of Justic2024/7/9
-
House Speaker Mike Johnson pledges vote for BIOSECURE as China-targeting bill hangs in limboAhead of an election in November—and amid a period of legislative uncertainty for the China-targeting BIOSECURE Act—U.S. House Speaker Mike Johnson (R - LA)has pledged to hold a vote for the controve2024/7/4
-
Lilly's Mounjaro triggers more weight loss than Novo Nordisk's Ozempic: studyIs Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? While a head-to-head trial pitting the two treatments remains ongoing, new evidence shows that Lilly’2024/7/4
-
J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the marketIt took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional nods. Regulators on both sides of the At2024/7/2
-
Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administrationSince Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea. Friday, Roche took another step in its advancement of the2024/7/2
-
With Boehringer ruling, industry extends legal losing streak against Medicare price negotiationsAs the process surrounding Medicare's drug price negotiations rolls on this summer—and as the pharmaceutical industry continues to loudly voice its complaints—another lawsuit contesting the legal via2024/6/27
-
China-made injectable PD-L1 drug flunks pivotal trial, forcing US partner to seek strategic optionsThe world’s first injectable immune checkpoint inhibitor likely won’t make it to the U.S. anytime soon after the China-approved drug flunked a pivotal trial in a rare cancer, forcing its stateside de2024/6/27
-
Emergent BioSolutions bags $250M in contract modifications to help boost US supply of medical countermeasuresWith four contract modifications totaling more than $250 million, the government is leveling up its agreements with long-time medical countermeasures supplier Emergent BioSolutions. The U.S. Departme2024/6/25
-
BIOSECURE Act hurts US biopharma industry's confidence in Chinese partners: surveyEven as theBIOSECURE Act charts an uncertain path through the legislative process, the draft bill has already seriously harmed the U.S. biopharma industry's perception of Chinese partners. Among U.S.2024/6/25
-
Biden joins Sanders' campaign targeting Novo Nordisk, Eli Lilly's diabetes and obesity drug pricesIn recent months, frequent pharma critic Sen. Bernie Sanders has beenratcheting up a campaignagainst Novo Nordisk over the price of its popular diabetes and weight loss medicines. Now, the senator ha2024/6/20